Fact based stock research
Assertio Therapeutics (NasdaqGS:ASRT)
US04545L1070
Assertio Therapeutics stock research in summary
Assertio Therapeutics shares have a market-typical stock price level. While they are good value, they show below average growth, and are riskily financed. We recommend evaluating whether the future of the company Assertio Therapeutics is typical for this industry which the market average price level of the shares suggests. If you believe that the future of the company is above average, that could be an argument for buying the shares and vice versa.
Latest Obermatt Ranks
| Value Rank | 57 |  |
| Growth Rank | 1 |  |
| Safety Rank | 1 | |
| Combined Rank | 10 | |
| Country | USA |
| Industry | Pharmaceuticals |
| Index | D.J. US Pharmaceutical, NASDAQ |
| Size class | Small |
January 29, 2021. Stock data may be delayed. Login to get the most recent research.
Google: Assertio Therapeutics
Research History: Assertio Therapeutics
| RESEARCH HISTORY | 2018 | 2019 | 2020 | 2021 | ||||
|---|---|---|---|---|---|---|---|---|
| VALUE | ||||||||
| VALUE | 34 |
|
60 |
|
62 |
|
57 |
|
| GROWTH | ||||||||
| GROWTH | 33 |
|
1 |
|
1 |
|
1 |
|
| SAFETY | ||||||||
| SAFETY | 29 |
|
14 |
|
1 |
|
1 |
|
| COMBINED | ||||||||
| COMBINED | 33 |
|
1 |
|
6 |
|
10 |
|
Value Metrics in Detail
| VALUE METRICS | 2018 | 2019 | 2020 | 2021 | ||||
|---|---|---|---|---|---|---|---|---|
| PRICE VS. REVENUES (P/S) | ||||||||
| PRICE VS. REVENUES (P/S) | 91 |
|
100 |
|
100 |
|
98 |
|
| PRICE VS. PROFITS (P/E) | ||||||||
| PRICE VS. PROFITS (P/E) | 10 |
|
29 |
|
25 |
|
24 |
|
| PRICE VS. CAPITAL (Market-to-Book) | ||||||||
| PRICE VS. CAPITAL (Market-to-Book) | 84 |
|
94 |
|
96 |
|
88 |
|
| DIVIDEND YIELD | ||||||||
| DIVIDEND YIELD | 1 |
|
1 |
|
1 |
|
1 |
|
| CONSOLIDATED RANK: VALUE | ||||||||
| CONSOLIDATED RANK: VALUE | 34 |
|
60 |
|
62 |
|
57 |
|
Growth Metrics in Detail
| GROWTH METRICS | 2018 | 2019 | 2020 | 2021 | ||||
|---|---|---|---|---|---|---|---|---|
| REVENUE GROWTH | ||||||||
| REVENUE GROWTH | 15 |
|
1 |
|
7 |
|
28 |
|
| PROFIT GROWTH | ||||||||
| PROFIT GROWTH | 78 |
|
38 |
|
12 |
|
18 |
|
| STOCK RETURNS | ||||||||
| STOCK RETURNS | 20 |
|
8 |
|
10 |
|
16 |
|
| CONSOLIDATED RANK: GROWTH | ||||||||
| CONSOLIDATED RANK: GROWTH | 33 |
|
1 |
|
1 |
|
1 |
|
Safety Metrics in Detail
| SAFETY METRICS | 2018 | 2019 | 2020 | 2021 | ||||
|---|---|---|---|---|---|---|---|---|
| LEVERAGE | ||||||||
| LEVERAGE | 10 |
|
1 |
|
8 |
|
8 |
|
| REFINANCING | ||||||||
| REFINANCING | 10 |
|
1 |
|
1 |
|
1 |
|
| LIQUIDITY | ||||||||
| LIQUIDITY | 64 |
|
64 |
|
17 |
|
27 |
|
| CONSOLIDATED RANK: SAFETY | ||||||||
| CONSOLIDATED RANK: SAFETY | 29 |
|
14 |
|
1 |
|
1 |
|
Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Assertio Therapeutics from January 29, 2021.
We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.